All lobbying filings

AVENUE SOLUTIONS

AVENUE SOLUTIONS filed a Q2 report for GENENTECH USA, INC. on July 21, 2025, reporting $50,000 in lobbying income.

Lobbying for GENENTECH USA, INC. · Biotechnology

All filings by AVENUE SOLUTIONS · Everything GENENTECH USA, INC. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Income

$50,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Issues related to healthcare access, quality and costs; Issues related to Medicare and Medicaid coverage and reimbursement; H.R. 946/S. 1862, ORPHAN Cures Act; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R.4299, Protecting Patient Access to Cancer and Complex Therapies Act

Health Issues

Issues related to 340b drug pricing program; Health care issues in H.R.1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21);

Bills named in this filing 5

H.R. 946
ORPHAN Cures Act
S. 1862
ORPHAN Cures Act
H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
H.R. 1
One Big Beautiful Bill Act
H. Con. Res. 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.